Efe Eworuke News Today

The risk for angioedema increases when switching from an ARB or ACE inhibitor to ARNI, observational data suggest. Better to start RAS inhibition using the ARNI in the first place, researchers say.

Amid debate over HF drug initiation and titration: a new study supports starting with sacubitril/valsartan, not switching to it.

This study uses 2 large US health care claims databases (Medicare fee-for-service and the US Food and Drug Administration’s Sentinel System) to examine systemic